Commentary

Video

Dr Li on Patient Outcomes From the KEYNOTE-057 Trial in BCG-Unresponsive NMIBC

Author(s):

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Roger Li, MD, genitourinary oncologist, Moffitt Cancer Center, discusses results from a post-hoc analysis of patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC) who did not respond to treatment with pembrolizumab (Keytruda) in the phase 2 KEYNOTE-057 trial (NCT02625961).

Primary results from KEYNOTE-057 demonstrated that pembrolizumab can serve as a bladder-sparing option for patients with high-risk NMIBC who are BCG-unresponsive and are unable or unwilling to undergo radical cystectomy. However, the outcomes of patients who do not respond to bladder-sparing therapies, including pembrolizumab, are of concern. Accordingly, Li and colleagues conducted a post hoc analysis of the KEYNOTE-057 trial to assess the clinical outcomes of patients who experienced persistent or recurrent high-risk NMIBC despite pembrolizumab therapy and subsequently received either radical cystectomy or other bladder-sparing therapies.

The analysis focused on progression-free survival (PFS), metastasis-free survival (MFS), and overall survival (OS), Li says. Patients with BCG-unresponsive carcinoma in situ (CIS) and/or papillary-only tumors who had nonresponse during treatment with pembrolizumab were divided into 3 different groups based on the timing of their radical cystectomy after non-response to pembrolizumab, using the 4-month mark as a categorization point, he explains. These groups included patients who underwent immediate radical cystectomy within the first 4 months, those who had late radical cystectomy after 4 months, and those who did not undergo radical cystectomy at all, opting instead for other bladder-sparing therapies, Li details.

Key findings from this analysis were presented at the 2024 ASCO Annual Meeting, and revealed no significant differences in PFS, MFS, or OS among these 3 groups, Li reports. Additionally, a comparison of patients who underwent radical cystectomy within the first 4 months vs those who had it after 4 months showed no difference in the distribution of pathological staging. These findings suggest that the timing of radical cystectomy following non-response to pembrolizumab does not impact key survival outcomes and that patients may have flexible options for managing persistent or recurrent high-risk NMIBC after pembrolizumab therapy, he concludes.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD